AlzeCure rights issue ends 329% oversubscribed, adds 22,982,891 shares

  • AlzeCure reported final results of its rights issue, with subscriptions reaching about 329% by the June 30 deadline.
  • About 21,761,664 shares, roughly 95% of the offer, were subscribed via subscription rights.
  • Another 53,860,151 shares were subscribed without subscription rights, implying heavy oversubscription and scaling in allocations.
  • Share capital is set to rise by SEK 574,572.275 to SEK 3,447,433.65 once the issue is registered.
  • Total shares are set to increase by 22,982,891 to 137,897,346, with registration expected in week 28.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.